Canada Pension Plan Investment Board Sells 78,976 Shares of Moderna, Inc. (NASDAQ:MRNA)

Canada Pension Plan Investment Board lessened its holdings in Moderna, Inc. (NASDAQ:MRNAFree Report) by 17.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 369,756 shares of the company’s stock after selling 78,976 shares during the period. Canada Pension Plan Investment Board owned about 0.10% of Moderna worth $38,192,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of MRNA. First Pacific Financial purchased a new stake in shares of Moderna in the 3rd quarter worth approximately $27,000. ICA Group Wealth Management LLC purchased a new stake in shares of Moderna in the 4th quarter worth approximately $27,000. Stonebridge Capital Advisors LLC lifted its position in shares of Moderna by 79.1% in the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock worth $49,000 after purchasing an additional 125 shares during the period. Ancora Advisors LLC lifted its position in shares of Moderna by 41.2% in the 1st quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after purchasing an additional 96 shares during the period. Finally, GPS Wealth Strategies Group LLC lifted its position in Moderna by 54.1% during the third quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock valued at $53,000 after acquiring an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 64.51% of the company’s stock.

Moderna Stock Down 6.7 %

NASDAQ:MRNA opened at $87.41 on Friday. The firm has a market capitalization of $33.33 billion, a P/E ratio of -9.35 and a beta of 1.69. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $177.37. The company’s fifty day moving average price is $96.62 and its 200-day moving average price is $96.18. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.46 and a quick ratio of 2.35.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group decreased their target price on shares of Moderna from $269.00 to $231.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Deutsche Bank Aktiengesellschaft cut shares of Moderna from a “hold” rating to a “sell” rating and decreased their target price for the company from $125.00 to $60.00 in a research report on Thursday, November 2nd. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and decreased their target price for the company from $89.00 to $69.00 in a research report on Friday, November 3rd. JPMorgan Chase & Co. decreased their target price on shares of Moderna from $93.00 to $90.00 and set a “neutral” rating for the company in a research report on Friday, December 1st. Finally, Canaccord Genuity Group began coverage on shares of Moderna in a research report on Wednesday, November 29th. They set a “hold” rating and a $82.00 target price for the company. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $123.96.

Read Our Latest Research Report on MRNA

Insider Transactions at Moderna

In other news, President Stephen Hoge sold 45,000 shares of the stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $100.01, for a total value of $4,500,450.00. Following the sale, the president now owns 1,531,063 shares in the company, valued at $153,121,610.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO James M. Mock sold 772 shares of the firm’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $109.75, for a total transaction of $84,727.00. Following the sale, the chief financial officer now owns 3,632 shares in the company, valued at $398,612. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Stephen Hoge sold 45,000 shares of the firm’s stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $100.01, for a total transaction of $4,500,450.00. Following the sale, the president now owns 1,531,063 shares in the company, valued at approximately $153,121,610.63. The disclosure for this sale can be found here. Insiders have sold 106,899 shares of company stock worth $10,732,838 over the last 90 days. 15.70% of the stock is currently owned by company insiders.

Moderna Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Read More

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.